This brief summary details an innovative pharmacist-led program addressing South Carolina’s opioid epidemic by integrating medication-assisted treatment (MAT) directly into pharmacy settings. The model enables pharmacists to administer long-acting injectables (Sublocade, Brixadi, Vivitrol), manage insurance and pre-authorizations, provide patient education, and coordinate care with prescribers. Early results show strong engagement: monthly processed prescriptions rose from 40 in October 2024 to 397 in September 2025, with patients averaging four months of treatment—surpassing key retention milestones. Surveys found 100% of patients reported improved adherence, and two-thirds of providers gained better understanding of LAI options. With new grant funding, the program’s second year will expand to rural areas, add copay assistance, and upgrade facilities, positioning Dottie’s model as a scalable, stigma-reducing approach to improving access and outcomes in opioid use disorder care.
Download the full report here.
